Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Net Income (2020 - 2025)

Historic Net Income for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to -$16.4 million.

  • Treace Medical Concepts' Net Income fell 650.2% to -$16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.6 million, marking a year-over-year increase of 1820.3%. This contributed to the annual value of -$56.1 million for FY2024, which is 1242.86% down from last year.
  • Per Treace Medical Concepts' latest filing, its Net Income stood at -$16.4 million for Q3 2025, which was down 650.2% from -$17.5 million recorded in Q2 2025.
  • Treace Medical Concepts' 5-year Net Income high stood at -$619000.0 for Q4 2024, and its period low was -$21.3 million during Q2 2024.
  • Moreover, its 5-year median value for Net Income was -$12.4 million (2023), whereas its average is -$11.3 million.
  • In the last 5 years, Treace Medical Concepts' Net Income plummeted by 35788.86% in 2021 and then surged by 9029.32% in 2024.
  • Over the past 5 years, Treace Medical Concepts' Net Income (Quarter) stood at -$6.6 million in 2021, then skyrocketed by 38.75% to -$4.1 million in 2022, then plummeted by 57.26% to -$6.4 million in 2023, then skyrocketed by 90.29% to -$619000.0 in 2024, then crashed by 2546.2% to -$16.4 million in 2025.
  • Its Net Income stands at -$16.4 million for Q3 2025, versus -$17.5 million for Q2 2025 and -$16.1 million for Q1 2025.